Tag: calcitonin gene-related peptide (CGRP)

1. Rimegepant significantly reduced the mean number of migraine days per month between the last 4 weeks of treatment and the observation period compared to placebo (-4.3 days vs. -3.5 days). 2. Patients in both groups were equally likely to have an adverse event and most events were mild-moderate in...

1. Patients with episode cluster headaches randomized to receive galcanezumab experienced a greater decline in frequency of headaches 1 to 3 weeks after treatment compared to placebo treated patients. 2. Injection-site pain occurred in patients receiving galcanezumab, though no notable differences in overall adverse events was seen between treatment and...

1. Patients with episode cluster headaches randomized to receive galcanezumab experienced a greater decline in frequency of headaches 1 to 3 weeks after treatment compared to placebo treated patients. 2. Injection-site pain occurred in patients receiving galcanezumab, though no notable differences in overall adverse events was seen between treatment and...